Format

Send to

Choose Destination
See comment in PubMed Commons below
Methods. 2009 Jun;48(2):193-9. doi: 10.1016/j.ymeth.2009.03.021. Epub 2009 Apr 9.

Molecular imaging of prostate cancer.

Author information

  • 1Department of Nuclear Medicine, University Hospital Gasthuisberg, Herestraat 49, Bus 7003, B-3000 Leuven, Belgium. Kimy.Emonds@med.kuleuven.be

Abstract

Prostate carcinoma is the most common non-cutaneous malignancy in males. Imaging of prostatic lesions is of great importance and aids in oncologic management and monitoring of therapy response. Particularly molecular imaging based on positron emission tomography (PET) and single photon emission computerized tomography (SPECT) has great potential. Using radio-labelled molecular probes, these approaches are highly sensitive and can provide key molecular and functional information on tumours. The identification of suitable targets based on unique genetic and biochemical features of cancer lesions is one of the core activities driving progress in molecular imaging of pathological processes. Nowadays, mainly metabolic probes are being used routinely for detection and staging of prostate cancer. The development of new specific receptor ligands and targeted probes and antibodies holds great promise to further enhance the performance of molecular imaging and to further improve the diagnosis and monitoring of prostate cancer.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk